192 related articles for article (PubMed ID: 30224768)
1. Serotonin receptor type 1B constitutes a therapeutic target for MDS and CMML.
Banús-Mulet A; Etxabe A; Cornet-Masana JM; Torrente MÁ; Lara-Castillo MC; Palomo L; Nomdedeu M; Díaz-Beyá M; Solé F; Nomdedeu B; Esteve J; Risueño RM
Sci Rep; 2018 Sep; 8(1):13883. PubMed ID: 30224768
[TBL] [Abstract][Full Text] [Related]
2. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.
Invernizzi R; Travaglino E; Benatti C; Malcovati L; Della Porta M; Cazzola M; Ascari E
Eur J Haematol; 2006 Jun; 76(6):494-501. PubMed ID: 16529600
[TBL] [Abstract][Full Text] [Related]
3. Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme.
van der Helm LH; Alhan C; Wijermans PW; van Marwijk Kooy M; Schaafsma R; Biemond BJ; Beeker A; Hoogendoorn M; van Rees BP; de Weerdt O; Wegman J; Libourel WJ; Luykx-de Bakker SA; Minnema MC; Brouwer RE; Croon-de Boer F; Eefting M; Jie KS; van de Loosdrecht AA; Koedam J; Veeger NJ; Vellenga E; Huls G
Br J Haematol; 2011 Dec; 155(5):599-606. PubMed ID: 21981697
[TBL] [Abstract][Full Text] [Related]
4. PDE4 Differential Expression Is a Potential Prognostic Factor and Therapeutic Target in Patients With Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia.
Chamseddine AN; Cabrero M; Wei Y; Ganan-Gomez I; Colla S; Takahashi K; Yang H; Bohannan ZS; Garcia-Manero G
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S67-73. PubMed ID: 27521329
[TBL] [Abstract][Full Text] [Related]
5. Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary Tale.
Ramadan H; Duong VH; Al Ali N; Padron E; Zhang L; Lancet JE; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S64-6. PubMed ID: 27521328
[TBL] [Abstract][Full Text] [Related]
6. How I treat chronic myelomonocytic leukemia.
Solary E; Itzykson R
Blood; 2017 Jul; 130(2):126-136. PubMed ID: 28572287
[TBL] [Abstract][Full Text] [Related]
7. Genetic and epigenetic factors interacting with clonal hematopoiesis resulting in chronic myelomonocytic leukemia.
Carr RM; Patnaik MM
Curr Opin Hematol; 2020 Jan; 27(1):2-10. PubMed ID: 31688455
[TBL] [Abstract][Full Text] [Related]
8. 5-Azacytidine modulates CpG methylation levels of EZH2 and NOTCH1 in myelodysplastic syndromes.
Gawlitza AL; Speith J; Rinke J; Sajzew R; Müller EK; Schäfer V; Hochhaus A; Ernst T
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2835-2843. PubMed ID: 31506740
[TBL] [Abstract][Full Text] [Related]
9. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
[TBL] [Abstract][Full Text] [Related]
10. Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series.
Martin de Frémont G; Hirsch P; Gimenez de Mestral S; Moguelet P; Ditchi Y; Emile JF; Senet P; Georgin-Lavialle S; Hanslik T; Maurier F; Adedjouma A; Abisror N; Mahevas T; Malard F; Adès L; Fenaux P; Fain O; Chasset F; Mekinian A
Front Immunol; 2021; 12():715053. PubMed ID: 34671345
[TBL] [Abstract][Full Text] [Related]
11. LILRB4 expression in chronic myelomonocytic leukemia and myelodysplastic syndrome based on response to hypomethylating agents.
Chien KS; Class CA; Montalban-Bravo G; Wei Y; Sasaki K; Naqvi K; Ganan-Gomez I; Yang H; Soltysiak KA; Kanagal-Shamanna R; Do KA; Kantarjian HM; Garcia-Manero G
Leuk Lymphoma; 2020 Jun; 61(6):1493-1499. PubMed ID: 32036728
[TBL] [Abstract][Full Text] [Related]
12. Increasing recognition and emerging therapies argue for dedicated clinical trials in chronic myelomonocytic leukemia.
Renneville A; Patnaik MM; Chan O; Padron E; Solary E
Leukemia; 2021 Oct; 35(10):2739-2751. PubMed ID: 34175902
[TBL] [Abstract][Full Text] [Related]
13. Transcriptomic Signatures of Hypomethylating Agent Failure in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
Darbaniyan F; Zheng H; Kanagal-Shamanna R; Lockyer P; Montalban-Bravo G; Estecio M; Lu Y; Soltysiak KA; Chien KS; Yang H; Sasaki K; Class C; Ganan-Gomez I; Do KA; Garcia-Manero G; Wei Y
Exp Hematol; 2022 Nov; 115():44-53. PubMed ID: 36150563
[TBL] [Abstract][Full Text] [Related]
14. A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.
Garcia-Manero G; Sekeres MA; Egyed M; Breccia M; Graux C; Cavenagh JD; Salman H; Illes A; Fenaux P; DeAngelo DJ; Stauder R; Yee K; Zhu N; Lee JH; Valcarcel D; MacWhannell A; Borbenyi Z; Gazi L; Acharyya S; Ide S; Marker M; Ottmann OG
Leukemia; 2017 Dec; 31(12):2799-2806. PubMed ID: 28546581
[TBL] [Abstract][Full Text] [Related]
15. Role of cedazuridine/decitabine in the management of myelodysplastic syndrome and chronic myelomonocytic leukemia.
Thota S; Oganesian A; Azab M; Griffiths EA
Future Oncol; 2021 Jun; 17(16):2077-2087. PubMed ID: 33709786
[TBL] [Abstract][Full Text] [Related]
16. Current management of patients with chronic myelomonocytic leukemia.
Mora E; Sanz GF
Curr Opin Oncol; 2018 Nov; 30(6):409-417. PubMed ID: 30169461
[TBL] [Abstract][Full Text] [Related]
17. Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?
Michaux JL; Martiat P
Leuk Lymphoma; 1993 Jan; 9(1-2):35-41. PubMed ID: 8477199
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of serotonin receptor type 1 in acute myeloid leukemia impairs leukemia stem cell functionality: a promising novel therapeutic target.
Etxabe A; Lara-Castillo MC; Cornet-Masana JM; Banús-Mulet A; Nomdedeu M; Torrente MA; Pratcorona M; Díaz-Beyá M; Esteve J; Risueño RM
Leukemia; 2017 Nov; 31(11):2288-2302. PubMed ID: 28193998
[TBL] [Abstract][Full Text] [Related]
19. [Significance and application value of multiparameter flow cytometry for differentiation of immunophenotype in chronic myelomonocytic leukemia, myelodysplastic syndrome and acute monocytic leukemia].
Wang YX; Zhang JH; Hu YP; Cao FF; Zhang N; Chen F; Liu X; Zhang MY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):857-62. PubMed ID: 22931642
[TBL] [Abstract][Full Text] [Related]
20. Antitumour activity of trabectedin in myelodysplastic/myeloproliferative neoplasms.
Romano M; Della Porta MG; Gallì A; Panini N; Licandro SA; Bello E; Craparotta I; Rosti V; Bonetti E; Tancredi R; Rossi M; Mannarino L; Marchini S; Porcu L; Galmarini CM; Zambelli A; Zecca M; Locatelli F; Cazzola M; Biondi A; Rambaldi A; Allavena P; Erba E; D'Incalci M
Br J Cancer; 2017 Jan; 116(3):335-343. PubMed ID: 28072764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]